These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32499299)

  • 1. First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer.
    Abbott JM; Zhou Q; Esquer H; Pike L; Broneske TP; Rinaldetti S; Abraham AD; Ramirez DA; Lunghofer PJ; Pitts TM; Regan DP; Tan AC; Gustafson DL; Messersmith WA; LaBarbera DV
    Mol Cancer Ther; 2020 Aug; 19(8):1598-1612. PubMed ID: 32499299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L.
    Prigaro BJ; Esquer H; Zhou Q; Pike LA; Awolade P; Lai XH; Abraham AD; Abbott JM; Matter B; Kompella UB; Messersmith WA; Gustafson DL; LaBarbera DV
    J Med Chem; 2022 Mar; 65(5):3943-3961. PubMed ID: 35192363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion.
    Chen L; Yuan YF; Li Y; Chan TH; Zheng BJ; Huang J; Guan XY
    Gut; 2011 Apr; 60(4):534-43. PubMed ID: 21068133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHD1L promotes tumor progression and predicts survival in colorectal carcinoma.
    Ji X; Li J; Zhu L; Cai J; Zhang J; Qu Y; Zhang H; Liu B; Zhao R; Zhu Z
    J Surg Res; 2013 Nov; 185(1):84-91. PubMed ID: 23746766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromodomain Helicase/ATPase DNA-Binding Protein 1-Like Gene (CHD1L) Expression and Implications for Invasion and Metastasis of Breast Cancer.
    Mu QJ; Li HL; Yao Y; Liu SC; Yin CG; Ma XZ
    PLoS One; 2015; 10(11):e0143030. PubMed ID: 26599012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHD1L promotes EOC cell invasiveness and metastasis via the regulation of METAP2.
    He WP; Guo YY; Yang GP; Lai HL; Sun TT; Zhang ZW; Ouyang LL; Zheng Y; Tian LM; Li XH; You ZS; Xie D; Yang GF
    Int J Med Sci; 2020; 17(15):2387-2395. PubMed ID: 32922205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
    He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
    Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.
    Fan GT; Ling ZH; He ZW; Wu SJ; Zhou GX
    Biochem Biophys Res Commun; 2021 May; 554():214-221. PubMed ID: 33813077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer.
    Li Y; He LR; Gao Y; Zhou NN; Liu Y; Zhou XK; Liu JF; Guan XY; Ma NF; Xie D
    Cell Death Dis; 2019 Feb; 10(2):99. PubMed ID: 30718500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients.
    Chen L; Chan TH; Yuan YF; Hu L; Huang J; Ma S; Wang J; Dong SS; Tang KH; Xie D; Li Y; Guan XY
    J Clin Invest; 2010 Apr; 120(4):1178-91. PubMed ID: 20335658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer.
    Abraham AD; Esquer H; Zhou Q; Tomlinson N; Hamill BD; Abbott JM; Li L; Pike LA; Rinaldetti S; Ramirez DA; Lunghofer PJ; Gomez JD; Schaack J; Nemkov T; D'Alessandro A; Hansen KC; Gustafson DL; Messersmith WA; LaBarbera DV
    J Med Chem; 2019 Nov; 62(22):10182-10203. PubMed ID: 31675229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The validation of new CHD1L inhibitors as a therapeutic strategy for cancer.
    Clune S; Awolade P; Zhou Q; Esquer H; Matter B; Kearns JT; Kellett T; Akintayo DC; Kompella UB; LaBarbera DV
    Biomed Pharmacother; 2024 Jan; 170():116037. PubMed ID: 38128184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHD1L Expression Increases Tumor Progression and Acts as a Predictive Biomarker for Poor Prognosis in Pancreatic Cancer.
    Liu C; Fu X; Zhong Z; Zhang J; Mou H; Wu Q; Sheng T; Huang B; Zou Y
    Dig Dis Sci; 2017 Sep; 62(9):2376-2385. PubMed ID: 28646284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pien Tze Huang inhibits liver metastasis by targeting TGF-β signaling in an orthotopic model of colorectal cancer.
    Lin W; Zhuang Q; Zheng L; Cao Z; Shen A; Li Q; Fu C; Feng J; Peng J
    Oncol Rep; 2015 Apr; 33(4):1922-8. PubMed ID: 25653118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1.
    Juneja M; Kobelt D; Walther W; Voss C; Smith J; Specker E; Neuenschwander M; Gohlke BO; Dahlmann M; Radetzki S; Preissner R; von Kries JP; Schlag PM; Stein U
    PLoS Biol; 2017 Jun; 15(6):e2000784. PubMed ID: 28570591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
    Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
    Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diverse LEF/TCF Expression in Human Colorectal Cancer Correlates with Altered Wnt-Regulated Transcriptome in a Meta-Analysis of Patient Biopsies.
    Mayer CD; Giclais SM; Alsehly F; Hoppler S
    Genes (Basel); 2020 May; 11(5):. PubMed ID: 32403323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OVOL2, an Inhibitor of WNT Signaling, Reduces Invasive Activities of Human and Mouse Cancer Cells and Is Down-regulated in Human Colorectal Tumors.
    Ye GD; Sun GB; Jiao P; Chen C; Liu QF; Huang XL; Zhang R; Cai WY; Li SN; Wu JF; Liu YJ; Wu RS; Xie YY; Chan EC; Liou YC; Li BA
    Gastroenterology; 2016 Mar; 150(3):659-671.e16. PubMed ID: 26619963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphological screening of mesenchymal mammary tumor organoids to identify drugs that reverse epithelial-mesenchymal transition.
    Zhao N; Powell RT; Yuan X; Bae G; Roarty KP; Stossi F; Strempfl M; Toneff MJ; Johnson HL; Mani SA; Jones P; Stephan CC; Rosen JM
    Nat Commun; 2021 Jul; 12(1):4262. PubMed ID: 34253738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence of CHD1L over-expression is associated with aggressive tumor biology and is a novel prognostic biomarker for patient survival in human breast cancer.
    Wu J; Zong Y; Fei X; Chen X; Huang O; He J; Chen W; Li Y; Shen K; Zhu L
    PLoS One; 2014; 9(8):e98673. PubMed ID: 25153161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.